Yosuke Nakagawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yosuke Nakagawa has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Hirotaka Komaba
Tokai University School of Medicine
5 shared publications Genta Kanai
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan
2 shared publications- Masafumi Fukagawa
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine , Isehara
2 shared publications Takehiko Wada
Tokai University School of Medicine
2 shared publicationsAbul Fajol
Tokai University School of Medicine
1 shared publication- Akihisa Takahashi
Gunma University Heavy Ion Medical Center, Maebashi, Gunma 371-8511, Japan
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F622-F631
FGF23 regulates phosphate and vitamin D metabolism during acute kidney injury and recovery
Acute kidney injury (AKI) induces a rapid increase in fibroblast growth factor 23 (FGF23). We show that the acute rise in FGF23 functions as an adaptive response to promote phosphaturia and mitigate hyperphosphatemia, at the cost of reduced 1,25-dihydroxyvitamin D and secondary hyperparathyroidism. Pharmacological FGFR inhibition disrupts this response, leading to sustained hyperphosphatemia. These findings identify FGF23 as a key early regulator of mineral homeostasis during AKI and recovery.
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F622-F631
Open AccessFGF23 regulates phosphate and vitamin D metabolism during acute kidney injury and recovery
Acute kidney injury (AKI) induces a rapid increase in fibroblast growth factor 23 (FGF23). We show that the acute rise in FGF23 functions as an adaptive response to promote phosphaturia and mitigate hyperphosphatemia, at the cost of reduced 1,25-dihydroxyvitamin D and secondary hyperparathyroidism. Pharmacological FGFR inhibition disrupts this response, leading to sustained hyperphosphatemia. These findings identify FGF23 as a key early regulator of mineral homeostasis during AKI and recovery.
- 19 March 2026
- Published by Elsevier in Kidney International
- Vol. 109 (4) , 801
Catheter malposition in a peritoneal dialysis patient with Chilaiditi sign
- 19 March 2026
- Published by Elsevier in Kidney International
- Vol. 109 (4) , 801
Catheter malposition in a peritoneal dialysis patient with Chilaiditi sign
- Open Access
- 29 October 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (11) , 6075-6079
Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review
Recent advances in multiple myeloma (MM) treatment, including bispecific antibodies (BsAbs), have improved outcomes. Elranatamab, a BsAb targeting B-cell maturation antigen and CD3, has shown efficacy in relapsed/refractory MM (RRMM). However, its use in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) is not well documented, as clinical trials often exclude this population. We report a 72-year-old woman with RRMM and ESRD on HD who was successfully treated with elranatamab after multiple prior therapies. She achieved a stringent complete response with undetectable minimal residual disease. Adverse events included grade 1 cytokine release syndrome, mild hypotension, and acute cholangitis, all resolved with appropriate management. Our literature review suggests BsAbs can be effective and generally well-tolerated in RRMM patients with ESRD on HD, although infection risk warrants caution. This report highlights elranatamab as a promising option for this vulnerable population. While initial responses and safety appear favourable, further studies are required to establish long-term outcomes.
- 29 October 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (11) , 6075-6079
Open AccessEfficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review
Recent advances in multiple myeloma (MM) treatment, including bispecific antibodies (BsAbs), have improved outcomes. Elranatamab, a BsAb targeting B-cell maturation antigen and CD3, has shown efficacy in relapsed/refractory MM (RRMM). However, its use in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) is not well documented, as clinical trials often exclude this population. We report a 72-year-old woman with RRMM and ESRD on HD who was successfully treated with elranatamab after multiple prior therapies. She achieved a stringent complete response with undetectable minimal residual disease. Adverse events included grade 1 cytokine release syndrome, mild hypotension, and acute cholangitis, all resolved with appropriate management. Our literature review suggests BsAbs can be effective and generally well-tolerated in RRMM patients with ESRD on HD, although infection risk warrants caution. This report highlights elranatamab as a promising option for this vulnerable population. While initial responses and safety appear favourable, further studies are required to establish long-term outcomes.
- Open Access
- 30 June 2024
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 39 (3) , 407-415
Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease
Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) each play a central role in the pathogenesis of chronic kidney disease (CKD)-mineral and bone disorder. Levels of both hormones increase progressively in advanced CKD and can lead to damage in multiple organs. Secondary hyperparathyroidism (SHPT), characterized by parathyroid hyperplasia with increased PTH secretion, is associated with fractures and mortality. Emerging evidence suggests that these associations may be partially explained by PTH-induced browning of adipose tissue and increased energy expenditure. Observational studies suggest a survival benefit of PTHlowering therapy, and a recent study comparing parathyroidectomy and calcimimetics further suggests the importance of intensive PTH control. The mechanisms underlying the regulation of FGF23 secretion by osteocytes in response to phosphate load have been unclear, but recent experimental studies have identified glycerol-3-phosphate, a byproduct of glycolysis released by the kidney, as a key regulator of FGF23 production. Elevated FGF23 levels have been shown to be associated with mortality, and experimental data suggest off-target adverse effects of FGF23. However, the causal role of FGF23 in adverse outcomes in CKD patients remains to be established. Further studies are needed to determine whether intensive SHPT control improves clinical outcomes and whether treatment targeting FGF23 can improve patient outcomes.
- 30 June 2024
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 39 (3) , 407-415
Open AccessRoles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease
Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) each play a central role in the pathogenesis of chronic kidney disease (CKD)-mineral and bone disorder. Levels of both hormones increase progressively in advanced CKD and can lead to damage in multiple organs. Secondary hyperparathyroidism (SHPT), characterized by parathyroid hyperplasia with increased PTH secretion, is associated with fractures and mortality. Emerging evidence suggests that these associations may be partially explained by PTH-induced browning of adipose tissue and increased energy expenditure. Observational studies suggest a survival benefit of PTHlowering therapy, and a recent study comparing parathyroidectomy and calcimimetics further suggests the importance of intensive PTH control. The mechanisms underlying the regulation of FGF23 secretion by osteocytes in response to phosphate load have been unclear, but recent experimental studies have identified glycerol-3-phosphate, a byproduct of glycolysis released by the kidney, as a key regulator of FGF23 production. Elevated FGF23 levels have been shown to be associated with mortality, and experimental data suggest off-target adverse effects of FGF23. However, the causal role of FGF23 in adverse outcomes in CKD patients remains to be established. Further studies are needed to determine whether intensive SHPT control improves clinical outcomes and whether treatment targeting FGF23 can improve patient outcomes.
- 27 December 2022
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 53 (11-12) , 767-774
Serum Sclerostin Levels and Mortality in Hemodialysis Patients: An 8-Year Prospective Study
Introduction: Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure. Sclerostin might be involved in the pathogenesis of vascular calcification, but few studies have examined the association between sclerostin and mortality in hemodialysis patients. Methods: We analyzed a prospective cohort of 654 patients undergoing maintenance hemodialysis. The primary exposure variable was the baseline serum sclerostin level measured at study enrollment. The primary outcome was 8-year all-cause mortality. Mortality risk was assessed using Cox regression models adjusted for potential confounders. Results: During a median follow-up of 7.6 years (interquartile range, 4.1–8.0 years), 229 of the 654 participants died. In a univariate analysis, serum sclerostin levels were not associated with mortality (HR per doubling, 0.94; 95% CI, 0.76–1.17). This result was unchanged after adjustment for age, sex, dialysis vintage, diabetes, prior cardiovascular disease, and body mass index (HR per doubling, 0.92; 95% CI, 0.72–1.17). Similar results were obtained for cardiovascular mortality. Conclusion: Serum sclerostin levels were not associated with mortality in maintenance hemodialysis patients. Further research is required to determine the role of sclerostin in vascular calcification and cardiovascular disease in kidney failure.
- 27 December 2022
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 53 (11-12) , 767-774
Serum Sclerostin Levels and Mortality in Hemodialysis Patients: An 8-Year Prospective Study
Introduction: Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure. Sclerostin might be involved in the pathogenesis of vascular calcification, but few studies have examined the association between sclerostin and mortality in hemodialysis patients. Methods: We analyzed a prospective cohort of 654 patients undergoing maintenance hemodialysis. The primary exposure variable was the baseline serum sclerostin level measured at study enrollment. The primary outcome was 8-year all-cause mortality. Mortality risk was assessed using Cox regression models adjusted for potential confounders. Results: During a median follow-up of 7.6 years (interquartile range, 4.1–8.0 years), 229 of the 654 participants died. In a univariate analysis, serum sclerostin levels were not associated with mortality (HR per doubling, 0.94; 95% CI, 0.76–1.17). This result was unchanged after adjustment for age, sex, dialysis vintage, diabetes, prior cardiovascular disease, and body mass index (HR per doubling, 0.92; 95% CI, 0.72–1.17). Similar results were obtained for cardiovascular mortality. Conclusion: Serum sclerostin levels were not associated with mortality in maintenance hemodialysis patients. Further research is required to determine the role of sclerostin in vascular calcification and cardiovascular disease in kidney failure.
- Open Access
- 1 January 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (1) , 59-67
Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation
- 1 January 2020
- Published by Elsevier in Kidney Medicine
- Vol. 2 (1) , 59-67
Open AccessChanges in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation
- Open Access
- 10 September 2017
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 34 (6) , 795-801
BRCA2 protects mammalian cells from heat shock
Heat shock induces DNA double-strand breaks (DSBs) in mammalian cells. Mammalian cells are capable of repairing DSBs by utilising the homologous recombination (HR) pathway. Breast cancer susceptibility gene 2 (BRCA2) is known to regulate the HR pathway. Here, we investigate the role of BRCA2 in repairing DNA damage induced by heat shock. Chinese hamster lung fibroblast cell lines and human tongue squamous cell carcinoma SAS cells were used. RAD51 foci formation assay was used as an HR indicator. Heat sensitivity was analysed with colony forming assays. Phosphorylated histone H2AX (γH2AX) intensity, which correlates with the number of DSBs, was analysed with flow cytometry. RAD51 foci appeared with heat shock, and the number of cells with RAD51 foci was maximal at about 4 h after heat shock. Heat-induced RAD51 foci co-localised with γH2AX foci. BRCA2-deficient cells were sensitive to heat when compared to their parental wild-type cells. Heat-induced γH2AX was higher in BRCA2-deficient cells compared to parental cells. In SAS cells, cells transfected with BRCA2-siRNA were more sensitive to heat than cells transfected with negative control siRNA. Apoptotic bodies increased in number more rapidly in BRCA2-siRNA transfected cells than in cells transfected with negative control siRNA when cells were observed at 48 h after a heat treatment. In addition, cells deficient in BRCA2 were incapable of activating heat-induced G2/M arrest. BRCA2 has a protecting role against heat-induced cell death. BRCA2 might be a potential molecular target for hyperthermic cancer therapy.
- 10 September 2017
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 34 (6) , 795-801
Open AccessBRCA2 protects mammalian cells from heat shock
Heat shock induces DNA double-strand breaks (DSBs) in mammalian cells. Mammalian cells are capable of repairing DSBs by utilising the homologous recombination (HR) pathway. Breast cancer susceptibility gene 2 (BRCA2) is known to regulate the HR pathway. Here, we investigate the role of BRCA2 in repairing DNA damage induced by heat shock. Chinese hamster lung fibroblast cell lines and human tongue squamous cell carcinoma SAS cells were used. RAD51 foci formation assay was used as an HR indicator. Heat sensitivity was analysed with colony forming assays. Phosphorylated histone H2AX (γH2AX) intensity, which correlates with the number of DSBs, was analysed with flow cytometry. RAD51 foci appeared with heat shock, and the number of cells with RAD51 foci was maximal at about 4 h after heat shock. Heat-induced RAD51 foci co-localised with γH2AX foci. BRCA2-deficient cells were sensitive to heat when compared to their parental wild-type cells. Heat-induced γH2AX was higher in BRCA2-deficient cells compared to parental cells. In SAS cells, cells transfected with BRCA2-siRNA were more sensitive to heat than cells transfected with negative control siRNA. Apoptotic bodies increased in number more rapidly in BRCA2-siRNA transfected cells than in cells transfected with negative control siRNA when cells were observed at 48 h after a heat treatment. In addition, cells deficient in BRCA2 were incapable of activating heat-induced G2/M arrest. BRCA2 has a protecting role against heat-induced cell death. BRCA2 might be a potential molecular target for hyperthermic cancer therapy.